MAPT and Alzheimer disease: The detection of amyloid-β (Aβ) and tau pathologies by cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers has enabled an in vivo biological diagnosis of Alzheimer’s disease (AD)1.